|1.||Levtchenko, Elena N: 11 articles (01/2015 - 10/2002)|
|2.||Dohil, Ranjan: 11 articles (04/2014 - 08/2003)|
|3.||Szabo, Sandor: 10 articles (02/2014 - 10/2003)|
|4.||Deng, Xiaoming: 10 articles (02/2014 - 10/2003)|
|5.||Khomenko, Tetyana: 10 articles (02/2014 - 10/2003)|
|6.||Gahl, William A: 9 articles (06/2015 - 12/2003)|
|7.||Schneider, Jerry A: 8 articles (12/2011 - 08/2003)|
|8.||Levtchenko, Elena: 7 articles (09/2014 - 09/2004)|
|9.||Barshop, Bruce A: 7 articles (04/2014 - 06/2006)|
|10.||Wannmacher, Clovis Milton Duval: 7 articles (12/2009 - 06/2004)|
12/01/2010 - "In conclusion, our experience shows a significant improvement in the renal and nonrenal complications of cystinosis over the past decades and highlights the importance of early diagnosis in order to initiate cysteamine as soon as possible."
07/01/1996 - "The concentrations of cysteamine that are effective against HIV-1 in vitro have been well tolerated over long periods by patients under treatment for cystinosis, an inherited disorder. "
01/01/1996 - "These results suggest that cysteamine may be an effective treatment of cystinosis encephalopathy and encourage prescription of this drug in cystinosis in order to prevent this complication."
01/01/1995 - "This method was used to re-analyse data on the efficacy of cysteamine treatment and to re-analyse new data on treating cystinosis patients with either of two doses of cysteamine (1.30 g/m2 per day and 1.95 g/m2 per day). "
03/01/2015 - "Cysteamine has improved survival and prognosis in cystinosis. "
04/29/1992 - "Duodenal CGRP-li is selectively decreased by the duodenal ulcerogen cysteamine during the acute phase of ulcers formation and might be among the local mediators which afford protection against the ulcerogenic stimuli."
03/01/2015 - "Other lines of evidence demonstrated the cytotoxic effect of cysteamine on duodenal mucosa leading to ulcer development. "
01/01/2012 - "Moreover, protection afforded by Extract A2 against cysteamine-induced duodenal lesions was evident from dose dependent decrease in ulcer index (p<0.05), score for intensity (p<0.05) and total lesion area (p<0.05), when compared with the control group. "
06/01/2006 - "An antisense oligonucleotide to egr-1 was used to inhibit the synthesis of Egr-1 and to determine its effect on ulcer formation in the rat model of cysteamine-induced duodenal ulceration. "
01/01/2004 - "Type 3 IAP was drastically diminished in duodenum of cysteamine-ulcer rats, but type 1 remained constant. "
|3.||Duodenal Ulcer (Curling's Ulcer)
02/01/2014 - "In this study, we hypothesized that STAT3 signaling is activated and provides a critical protective role that is required for enterocyte survival during the early phases of cysteamine-induced duodenal ulcers. "
04/01/2012 - "This study was aimed to document the preventive effects of Cochinchina momordica seed extract against cysteamine-induced duodenal ulcer as well as the elucidation of its pharmacological mechanisms. "
04/23/2004 - "Our recent studies demonstrated a critical role of enhanced transcriptional activity of early growth response factor-1 (Egr-1) in early stages of cysteamine-induced duodenal ulcer in rats. "
10/03/2003 - "Recent studies from our laboratory demonstrated that Egr-1 is upregulated in the rat duodenal mucosa during cysteamine-induced duodenal ulceration and that antisense egr-1 oligonucleotide aggravates the duodenal ulcers. "
09/01/1988 - "The present study suggested that the Brunner's glands, together with the crypts of Lieberkühn, play an important role in the healing process of cysteamine-induced duodenal ulcer."
|4.||Stomach Ulcer (Gastric Ulcer)
10/01/1991 - "The aim of this study is to elucidate the role on the sympathoadrenal medullary system in the pathogenesis of the cysteamine-induced gastric ulcer. "
10/01/1991 - "These results suggest that the capacity of the sympathetic nervous system in both the adrenal medulla and the stomach plays an important role in preventing the cysteamine-induced gastric ulcer in SHR."
10/01/1991 - "We previously reported that cysteamine induces severe gastric ulcers in WKY, but very mild in SHR. "
10/01/1991 - "[Inhibition of the cysteamine-induced gastric ulcer by the sympathoadrenal medullary system in spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto rats (WKY)]."
06/01/1988 - "As a result of duodenal and gastric ulcer index, ulcerogenicity of cysteamine in the stomach was concerned with dopaminergic mechanism more than that of in the duodenum. "
|5.||Huntington Disease (Huntington's Disease)
03/30/2011 - "Given the significant benefits observed in a Huntington's disease (HD) model, cysteamine has recently leaped to clinical trial. "
04/01/2006 - "In a single-center open-label study, we determined the maximum tolerable dose (MTD) and side effects of cysteamine in people with Huntington's disease. "
02/01/2015 - "A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease."
04/01/2006 - "We conclude that, at a dose of 20 mg/kg per day, cysteamine was tolerable in people with Huntington's disease. "
06/04/2010 - "Cysteamine exhibits strong antioxidant activity and has been implicated in the treatment of neurodegenerative disorders such as Huntington's disease. "
|5.||Ethanol (Ethyl Alcohol)
|6.||Aspirin (Acetylsalicylic Acid)
|10.||Glutathione (Reduced Glutathione)